Different Cycles of Neoadjuvant PD-1 Blockades + Chemotherapy for Advanced Gastric Cancer

StatusCompleted
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion date changed from estimate of Jan 31, 2025 to Jan 31, 2026 Show 7 more changesShow less
    • Trial completed
    • Final enrollment: 409 participants (planned 300)
    • Primary completion date changed from estimate of Jan 31, 2025 to May 31, 2025
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints revised (8)
    • Site details revised
    • Publications: details revised at 16 of 16 entries
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The goal of this observational study is to analyze the impact of different durations of neoadjuvant PD-1 inhibitor combined with chemotherapy on tumor regression and safety in patients with advanced gastric cancer. The main questions it aims to answer are: * Does the duration of neoadjuvant treatment influence tumor regression grading (TRG)? * How does treatment duration affect perioperative safety and clinical outcomes? Participants who have previously undergone neoadjuvant PD-1 inhibitor combined with chemotherapy followed by surgery as part of their routine medical care will have their clinical data retrospectively reviewed and analyzed.
Trial Details
NCT Number NCT06798376
Lead Sponsor Chinese PLA General Hospital
Conditions
(from sponsor)		 Gastric Adenocarcinoma
Enrollment 409 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov